• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients.

作者信息

Liu Dingxie, Hao Qiongyu, Li Jieqing, Li Qun, Wang Kun, Geng Qing, Wu Yutong, Vadgama Jaydutt V, Wu Yong

机构信息

Bluewater Biotech LLC, New Providence, NJ, 07974, USA.

Division of Cancer Research and Training, Department of Internal Medicine, Charles Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, 90095, USA.

出版信息

Cancer Commun (Lond). 2022 Jul;42(7):663-667. doi: 10.1002/cac2.12296. Epub 2022 Apr 29.

DOI:10.1002/cac2.12296
PMID:35486908
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9257990/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605f/9257990/7d117dbb428b/CAC2-42-663-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605f/9257990/7d117dbb428b/CAC2-42-663-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/605f/9257990/7d117dbb428b/CAC2-42-663-g001.jpg

相似文献

1
ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients.ZBED2表达增强干扰素信号传导，并预示雌激素受体阴性乳腺癌患者有更好的生存率。
Cancer Commun (Lond). 2022 Jul;42(7):663-667. doi: 10.1002/cac2.12296. Epub 2022 Apr 29.
2
Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling.主要组织相容性复合体I类分子在乳腺癌亚型中的差异表达与雌激素受体及干扰素信号传导相关。
Oncotarget. 2016 May 24;7(21):30119-32. doi: 10.18632/oncotarget.8798.
3
Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells.雌激素受体介导三阴性乳腺癌细胞的放射敏感性。
Med Sci Monit. 2017 Jun 1;23:2674-2683. doi: 10.12659/msm.904810.
4
G1P3, an interferon- and estrogen-induced survival protein contributes to hyperplasia, tamoxifen resistance and poor outcomes in breast cancer.G1P3，一种干扰素和雌激素诱导的生存蛋白，有助于乳腺癌的增生、他莫昔芬耐药和不良预后。
Oncogene. 2012 Apr 26;31(17):2222-36. doi: 10.1038/onc.2011.393. Epub 2011 Sep 26.
5
Androgen receptor expression predicts different clinical outcomes for breast cancer patients stratified by hormone receptor status.雄激素受体表达可预测按激素受体状态分层的乳腺癌患者的不同临床结局。
Oncotarget. 2016 Jul 5;7(27):41285-41293. doi: 10.18632/oncotarget.9778.
6
Characterization of macrophage--cancer cell crosstalk in estrogen receptor positive and triple-negative breast cancer.雌激素受体阳性和三阴性乳腺癌中巨噬细胞与癌细胞相互作用的特征分析
Sci Rep. 2015 Mar 17;5:9188. doi: 10.1038/srep09188.
7
Analysis of differentially expressed proteins between HER2 positive and triple negative breast cancer and their prognostic significance.分析 HER2 阳性和三阴性乳腺癌之间差异表达蛋白及其预后意义。
Ann Diagn Pathol. 2021 Dec;55:151834. doi: 10.1016/j.anndiagpath.2021.151834. Epub 2021 Sep 29.
8
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.三阴性乳腺癌细胞系：寻找三阴性乳腺癌更佳治疗方法的一种工具。
Breast Dis. 2010;32(1-2):35-48. doi: 10.3233/BD-2010-0307.
9
Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.角蛋白17在雌激素受体阴性/人表皮生长因子受体2阴性乳腺癌中过度表达，并预示着较差的生存率。
Hum Pathol. 2017 Apr;62:23-32. doi: 10.1016/j.humpath.2016.10.006. Epub 2016 Nov 2.
10
Interferon as a modifier of estrogen receptors.
Ann Clin Lab Sci. 1984 Jan-Feb;14(1):32-9.

引用本文的文献

1
ZBED4: A Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.ZBED4：肝细胞癌的一种预后生物标志物和治疗靶点
J Hepatocell Carcinoma. 2025 Aug 21;12:1873-1892. doi: 10.2147/JHC.S546808. eCollection 2025.
2
Identification of TUBB2A as a Cancer-Immunity Cycle-Related Therapeutic Target in Triple-Negative Breast Cancer.鉴定 TUBB2A 为三阴性乳腺癌中癌症免疫循环相关的治疗靶点。
Mol Biotechnol. 2024 Sep;66(9):2467-2480. doi: 10.1007/s12033-023-00880-2. Epub 2023 Sep 24.
3
Establishment of a prognostic model toward lung squamous cell carcinoma based on mG-related genes in the cancer genome atlas.

本文引用的文献

1
Basal-like breast cancer with low TGFβ and high TNFα pathway activity is rich in activated memory CD4 T cells and has a good prognosis.基底样乳腺癌中 TGFβ 通路活性低而 TNFα 通路活性高，这类肿瘤富含活化的记忆性 CD4 T 细胞，且预后良好。
Int J Biol Sci. 2021 Jan 30;17(3):670-682. doi: 10.7150/ijbs.56128. eCollection 2021.
2
In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer.基于计算机的整合素与免疫激活在基底样和 HER2+乳腺癌中的转录组图谱。
Cell Oncol (Dordr). 2021 Jun;44(3):569-580. doi: 10.1007/s13402-020-00583-9. Epub 2021 Jan 19.
3
Transcription Factors in Cancer Development and Therapy.
基于癌症基因组图谱中 mG 相关基因建立肺鳞癌预后模型。
Physiol Genomics. 2023 Oct 1;55(10):427-439. doi: 10.1152/physiolgenomics.00149.2022. Epub 2023 Aug 14.
4
Prognostic evaluation of pancreatic cancer based on the model of chemo-radiotherapy resistance-related genes.基于化疗放疗抵抗相关基因模型的胰腺癌预后评估
J Gastrointest Oncol. 2023 Jun 30;14(3):1525-1545. doi: 10.21037/jgo-23-308. Epub 2023 Jun 19.
癌症发展与治疗中的转录因子
Cancers (Basel). 2020 Aug 15;12(8):2296. doi: 10.3390/cancers12082296.
4
Identification of a prognostic LncRNA signature for ER-positive, ER-negative and triple-negative breast cancers.鉴定 ER 阳性、ER 阴性和三阴性乳腺癌的预后 LncRNA 特征。
Breast Cancer Res Treat. 2020 Aug;183(1):95-105. doi: 10.1007/s10549-020-05770-8. Epub 2020 Jun 29.
5
Recent therapeutic trends and promising targets in triple negative breast cancer.三阴性乳腺癌的最新治疗趋势和有前途的靶点。
Pharmacol Ther. 2019 Jul;199:30-57. doi: 10.1016/j.pharmthera.2019.02.006. Epub 2019 Feb 28.
6
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.一种基因特征可预测三阴性乳腺癌患者新辅助化疗后肿瘤浸润淋巴细胞高和结局。
Ann Oncol. 2018 Jan 1;29(1):162-169. doi: 10.1093/annonc/mdx691.
7
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.三阴性乳腺癌：一种异质性疾病的挑战与机遇
Nat Rev Clin Oncol. 2016 Nov;13(11):674-690. doi: 10.1038/nrclinonc.2016.66. Epub 2016 May 17.
8
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer.全面基因组分析确定三阴性乳腺癌的新亚型和靶点。
Clin Cancer Res. 2015 Apr 1;21(7):1688-98. doi: 10.1158/1078-0432.CCR-14-0432. Epub 2014 Sep 10.
9
Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.前瞻性转移性三阴性乳腺癌的基因组和转录组测序揭示了治疗弱点。
Mol Cancer Ther. 2013 Jan;12(1):104-16. doi: 10.1158/1535-7163.MCT-12-0781. Epub 2012 Nov 19.
10
Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.与乳腺癌临床结果相关的生物学过程取决于分子亚型。
Clin Cancer Res. 2008 Aug 15;14(16):5158-65. doi: 10.1158/1078-0432.CCR-07-4756.